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A new protocol for RhD-negative 
pregnant women?
Can cell-free DNA testing reduce unnecessary use of 
anti-D immunoglobulin in RhD-negative women and 
still prevent harm to their RhD-positive infants? 
PRACTICE CHANGER
Employ cell-free DNA testing at 27 weeks’ 
gestation in your RhD-negative obstetric pa-
tients to reduce unnecessary use of anti-D 
immunoglobulin.1
STRENGTH OF RECOMMENDATION 
B: Based on a single, prospective, cohort study.
de Haas M, Thurik FF, van der Ploeg CP, et al. Sensitivity of fetal RHD 
screening for safe guidance of targeted anti-D immunoglobulin pro-
phylaxis: prospective cohort study of a nationwide programme in the 
Netherlands. BMJ. 2016;355:i5789.
ILLUSTRATIVE CASE
A 30-year-old G1P0 woman presents to your 
office for routine obstetric care at 18 weeks’ 
gestation. Her pregnancy has been uncompli-
cated, but her prenatal lab evaluation is no-
table for blood type A-negative. She wants to 
know if she really needs the anti-D immune 
globulin injection.
Rhesus (Rh)D-negative women carry-ing an RhD-positive fetus are at risk of developing anti-D antibodies, placing 
the fetus at risk for HDFN (hemolytic disease 
of the fetus and newborn). If undiagnosed 
and/or untreated, HDFN carries significant 
risk of perinatal morbidity and mortality.2
With routine postnatal anti-D immuno-
globulin prophylaxis of RhD-negative women 
who delivered an RhD-positive child (which 
began around 1970), the risk of maternal al-
loimmunization was reduced from 16% to 
1.12%-1.3%.3-5 The risk was further reduced 
to approximately 0.28% with the addition of 
consistent prophylaxis at 28 weeks’ gesta-
tion.4 As a result, the current standard of care 
is to administer anti-D immunoglobulin at 
28 weeks’ gestation, within 72 hours of deliv-
ery of an RhD-positive fetus, and after events 
with risk of fetal-to-maternal transfusion (eg, 
spontaneous, threatened, or induced abor-
tion; invasive prenatal diagnostic procedures 
such as amniocentesis; blunt abdominal 
trauma; external cephalic version; second or 
third trimester antepartum bleeding).6
❚ The problem of unnecessary Tx. How-
ever, under this current practice, many 
RhD-negative women are receiving anti-D 
immunoglobulin unnecessarily. This is be-
cause the fetus’s RhD status is not routinely 
known during the prenatal period. 
❚ Enter cell-free DNA testing. Cell-free 
DNA testing analyzes fragments of fetal DNA 
found in maternal blood. The use of cell-free 
DNA testing at 10 to 13 weeks’ gestation to 
screen for fetal chromosomal abnormalities 
is reliable (91%-99% sensitivity for trisomies 
21, 18, and 137) and becoming increasingly 
more common. 
❚ A notable meta-analysis. A 2017 
meta-analysis of 30 studies of cell-free DNA 
testing of RhD status in the first and second 
trimester calculated a sensitivity of 99.3% 
(95% confidence interval [CI], 98.2-99.7) and 
a specificity of 98.4% (95% CI, 96.4-99.3).7 
Denmark, the Netherlands, Sweden, France, 
and Finland are using this method routinely. 
As of this writing, the American College of Ob-
stetricians and Gynecologists (ACOG) has not 
l~ ~ 
308 THE JOURNAL OF FAMILY PRACTICE  |   MAY 2018  |   VOL 67, NO 5
PURLs®
CONTINUED ON PAGE 319
recommended the use of cell-free DNA RhD 
testing in the United States, but they do note 
that as the cost of the assay declines, this 
method may become preferred.8 The National 
Institute for Health and Care Excellence in 
England recommends its use as long as its cost 
remains below a set threshold.9 
This study evaluated the accuracy of using 
cell-free DNA testing at 27 weeks’ gestation to 
determine fetal RhD status compared with se-
rologic typing of cord blood at delivery.
STUDY SUMMARY
Cell-free DNA test gets  
high marks in Netherlands trial
This large observational cohort trial from 
the Netherlands examined the accuracy of 
identifying RhD-positive fetuses using cell-
free DNA isolates in maternal plasma. Over 
the 15-month study period, fetal RhD testing 
was conducted during Week 27 of gestation, 
and results were compared with those ob-
tained using neonatal cord blood at birth. If 
the fetal RhD test was positive, providers ad-
ministered 200 mcg anti-D immunoglobulin 
during the 30th week of gestation and within 
48 hours of birth. If fetal RhD was negative, 
providers were told immunoglobulin was 
unnecessary. 
More than 32,000 RhD-negative women 
were screened. The cell-free DNA test showed 
fetal RhD-positive results 62% of the time 
and RhD-negative results in the remainder. 
Cord blood samples were available for 25,789 
pregnancies (80%). 
❚ Sensitivity, specificity. The sensitiv-
ity for identifying fetal RhD was 99% and 
the specificity was 98%. Both negative and 
positive predictive values were 99%. Over-
all, there were 225 false-positive results and 
9 false-negative results. In the 9 false nega-
tives, 6 were due to a lack of fetal DNA in the 
sample and 3 were due to technical error (de-
fined as an operator ignoring a failure of the 
robot pipetting the plasma or other technical 
failures). 
The false-negative rate (0.03%) was 
lower than the predetermined estimated false- 
negative rate of cord blood serology (0.25%). 
In 22 of the supposed false positives, follow-up 
serology or molecular testing found an RhD 
gene was actually present, meaning the results 
of the neonatal cord blood serology in these 
cases were falsely negative. If you recalculate 
with these data in mind, the false-negative rate 
for fetal DNA testing was actually less than half 
that of typical serologic determination. 
WHAT’S NEW
An accurate test with the potential  
to reduce unnecessary Tx
Fetal RhD testing at 27 weeks’ gestation ap-
pears to be highly accurate and could reduce 
the unnecessary use of anti-D immunoglob-
ulin when the fetal RhD is negative.
CAVEATS
Different results  
with different ethnicities?
Dutch participants are not necessarily reflec-
tive of the US population. Known variation in 
the rate of fetal RhD positivity among RhD-
negative pregnant women by race and eth-
nicity could mean that the number of women 
able to forego anti-D-immunoglobulin pro-
phylaxis would be different in the United 
States from that in other countries. 
Also, in this study, polymerase chain re-
action (PCR) for 2 RhD sequences was run in 
triplicate, and a computer-based algorithm 
was used to automatically score samples to 
provide results. For safe implementation, 
the cell-free fetal RhD DNA testing process 
would need to follow similar methods.
CHALLENGES TO IMPLEMENTATION
Test cost and availability are  
big unknowns
Cost and availability of the test may be barri-
ers, but there is currently too little informa-
tion on either subject in the United States 
to make a determination. A 2013 study indi-
cated that the use of cell-free DNA testing to 
determine fetal RhD status was then approxi-
mately $682.10                              JFP
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